Request addressed:  
Evaluate public dataset metadata and completed processed‑matrix analyses for MK‑hypoxia‑vascular remodeling validation.

Search context reviewed:  
Public Dataset Discovery Context – no programmatic repository hits were returned. The “Top Public Dataset Hits” table is empty. All validation opportunities must therefore rely on the two datasets listed in the Public Dataset Analysis Context.

Analysis context reviewed:  
Public Dataset Analysis Context – two datasets were downloaded and analysed using processed expression matrices:  
- **GSE289322** (19 samples; 8 case vs 4 control; 30 495 genes; candidate gene check + differential expression)  
- **GSE291455** (4 samples; 0 case vs 0 control; 58 302 genes; candidate gene check only; no DE possible)

Top dataset candidates:

Rank: 1  
Accession and source: GSE289322 (GEO processed matrix)  
Retrieved metadata: Not available; no title, organism, tissue, or modality described in the discovery context.  
Relevance class: Tissue‑level / recipient‑cell (based on availability of case‑control design; likely a bulk RNA‑seq or microarray experiment with enough samples for differential testing).  
Modality: Not specified; processed matrix suggests transcriptomics (microarray or RNA‑seq).  
Organism/tissue if available: Not provided.  
What it could validate:  
- Differential expression of MK‑related genes (Amd1, Amd2, Ldha, Cyp1a1, etc.) or metabolic‑pathway genes in the experimental condition versus control.  
- Presence/absence of candidate genes linked to metabolite‑enzyme‑remodelling chains.  
- Enrichment of pathways (polyamine metabolism, methionine salvage, glycolysis) if the DE results are explored beyond candidate genes.  
Completed analysis result, if any: Candidate gene check and DE results are stored; a full analysis report exists. The context does not list which genes were hit or the DE significance, but the matrix was parsed and analysed.  
What it cannot validate from metadata alone: MK‑cell specificity (the analysis is on whole‑tissue or mixed‑cell samples; cannot assign expression to MKs without cell‑type deconvolution or additional annotation).  
Priority: High – a case‑control design with DE results offers the strongest public‑data validation opportunity for direction‑level hypotheses, especially to check if candidate metabolic/enzymatic genes change in the lung/PH context.

Rank: 2  
Accession and source: GSE291455 (GEO processed matrix)  
Retrieved metadata: Not available.  
Relevance class: Broad context (low relevance for direct validation; no group labels).  
Modality: Not specified.  
Organism/tissue if available: Not provided.  
What it could validate: Only candidate gene expression (presence/absence) in the four available samples; no statistical comparison.  
Completed analysis result, if any: Candidate gene check performed; no differential analysis possible.  
What it cannot validate from metadata alone: Any hypoxia‑ or PH‑related change; cannot link to any condition.  
Priority: Low – usable only to confirm that a gene of interest is expressed in the profiled tissue, but offers no group‑contrast evidence.

Cross‑dataset summary:  
- Strongest public‑data validation opportunities: GSE289322 provides a case‑control contrast with DE results; it can be mined for expression changes in MK‑associated metabolic genes (e.g., Amd1, Ldha) or pathway biomarkers in lung/PH tissue.  
- Completed public‑data analyses: Two datasets analysed; one includes DE and candidate gene checks, the other only candidate expression.  
- Public‑data gaps: No single‑cell, spatial, proteomic, metabolomic, or MK‑enriched public datasets were retrieved or analysed. No dataset explicitly profiles megakaryocytes, platelets, or their secretome. MK‑origin evidence cannot be tested with the available public data.  
- Hypotheses or pathways especially suited for public‑data validation: Metabolomics‑driven hypotheses that converge on enzyme genes (Amd1, Amd2, Ldha, Cyp1a1) or pathways (polyamine, methionine salvage, glycolysis) can be probed by checking their differential expression in GSE289322. If those genes show disease‑associated shifts, they would add orthogonal tissue‑level support.  
- Hypotheses that still require new experiments: Any hypothesis requiring MK‑specific isolation, spatial localisation, metabolite/protein quantification, EV cargo, or direct MK‑to‑vascular cell signalling – the available public data cannot replace targeted experiments.

Evidence summary for downstream agents:  
- Strongly supported by completed public‑data analysis: Nothing can be claimed without inspecting the actual DE results and candidate gene lists. The files exist but their content is not summarised here.  
- Supported only by retrieved metadata: No metadata was retrieved; this category is empty.  
- Plausible but requiring dataset download/reanalysis: The two matrices are already processed at the expression‑matrix level, so limited re‑analysis could be done within the framework (e.g., re‑running gene set enrichment on the GSE289322 DE table). Full re‑analysis of raw data would require new downloads.  
- Unsupported or not found: MK‑specific profiling, spatial transcriptomics, metabolomics, or proteomics data. Hypoxia‑specific MK isolation and MK‑to‑vascular cell co‑culture experiments remain unaddressed by public datasets.  
- Recommended next retrieval or analysis step: Examine the candidate_gene_check.tsv and de_results.tsv files from GSE289322 for genes belonging to the mechanism‑ready shortlist (Amd1, Amd2, Ldha, Cyp1a1, Mat2a, Aldh2, Pnp, Nt5c2, etc.). If those genes show differential expression in the same direction (PH‑up) in lung/PH tissue, they would reinforce the metabolomics‑driven hypotheses. Additionally, run gene‑set enrichment on the DE results to see whether polyamine, methionine, or glycolysis pathways are altered at the tissue level. The GSE291455 dataset can be used to check baseline expression of candidate genes but provides no contrast information.
